The influenza treatment market, which had virtually disappeared after the spread of COVID-19, has revived for the first time in 3 years. With the number of flu patients surging due to the flu epidemic, the number of quarterly prescriptions soared from less than KRW 100 million to KRW 10 billion.

According to the market research institution UBIST on the 26th, outpatient prescriptions of oseltamivir in A4 last year had recorded KRW 10 billion. Oseltamivir is the most commonly used substance to treat influenza, and the original product is Roche's 'Tamiflu'. This is the first time since Q4 2018 that quarterly prescriptions of the substance recorded KRW 10 billion.